Prognostic Models of Primary Sclerosing Cholangitis
https://doi.org/10.22416/1382-4376-2022-32-5-43-50
Abstract
Aim: to study the significance of prognostic scales in a target group of patients with primary sclerosing cholangitis (PSC) living in the Chelyabinsk region.
Materials and methods. The study included 21 patients with a confirmed diagnosis of primary sclerosing cholangitis (PSC) and a disease duration of at least two years. The primary endpoint studied was death. The MELD, Mayo Risk Score, Amsterdam-Oxford PSC Score, PREsTo score, and UK-PSC Score scales were calculated based on the medical records. Statistical processing was carried out using the SPSS Statistics v.22 application.
Results. A retrospective assessment of the risk of mortality using the MELD, Mayo Risk Score and Amsterdam-
Oxford PSC Score did not reveal a statistically significant difference between deceased and surviving patients. The UK-PSC Score scale showed the highest predictive value (p = 0.046).
Conclusion. The new predictive model UK-PSC Score showed advantages in predicting death in PSC patients compared to other scales.
About the Authors
A. I. Dolgushina
South Ural State Medical University
Anastasia I. Dolgushina — Dr. Sci. (Med.), Associate Professor, Head of the Department of Hospital Therapy
454092, Chelyabinsk, Vorovskogo str., 64
A. A. Selyanina
South Ural State Medical University
Russian Federation
Russian Federation
Anna A. Selyanina — Assistant of the Department of Hospital Therapy
454092, Chelyabinsk, Vorovskogo str., 64
V. V. Dubrovina
South Ural State Medical University
Viktoria V. Dubrovina — 6th year student
454092, Chelyabinsk, Vorovskogo str., 64
G. A. Isyangildina
South Ural State Medical University
Gulnaz A. Isyangildina — 6th year student
454092, Chelyabinsk, Vorovskogo str., 64
E. R. Olevskaya
South Ural State Medical University; Chelyabinsk Regional Clinical Hospital
Elena R. Olevskaya — Dr. Sci. (Med.), Associate Professor, Head of the Department of Endoscopy
454092, Chelyabinsk, Vorovskogo str., 64
References
1. Ivashkin V.T., Shirokova E.N., Maevskaya M.V., Pavlov Ch.S., Shifrin O.S., Maev I.V., et al. Clinical recommendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver on the diagnosis and treatment of cholestasis. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(2):41–57 (In Russ.).
2. Chapman M.H., Thorburn D., Hirschfield G.M., Webster G.G.J., Rushbrook S.M., Alexander G., et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356–78. DOI: 10.1136/gutjnl-2018-317993
3. Lindor K.D., Kowdley K.V., Harrison M.E. American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646–59. DOI: 10.1038/ajg.2015.112
4. Ji S.G., Juran B.D., Mucha S., Folseraas T., Jostins L., Melum E., et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269–73. DOI: 10.1038/ng.3745
5. Karlsen T.H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis — a comprehensive review. J Hepatol. 2017;67(6):1298–323. DOI: 10.1016/j.jhep.2017.07.022
6. Molodecky N.A., Kareemi H., Parab R., Barkema H.W., Quan H., Myers R.P., Kaplan G.G. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9. DOI: 10.1002/hep.24247
7. Boonstra, K., Weersma, R.K., van Erpecum, K.J., Rauws, E.A., Spanier, B.W.M., Poen, A.C., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55. DOI: 10.1002/hep.26565
8. Vladut C., Ciocirlan M., Bilous D., ?andru V., Stan-Ilie M., Panic N., et al. An Overview on Primary Sclerosing Cholangitis. Journal of Clinical Medicine. 2020;9(3):754. DOI: 10.3390/jcm9030754
9. Pazenko E.V., Raykhelson K.L., Kondrashina E.A., Gabrusskaya T.V., Gerasimova O.A. Features of the course of primary sclerosing cholangitis, combined with inflammatory bowel diseases. EiCG. 2017;10(146): 33–39 (In Russ.).
10. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7. DOI: 10.1016/s0168-8278(01)00288-4
11. Tischendorf J.J., Hecker H., Kruger M., Manns M.P., Meier P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007;102(1):107–14. DOI: 10.1111/j.1572-0241.2006.00872.x
12. Weismuller T.J., Trivedi P.J., Bergquist A., Imam M., Lenzen H., Ponsioen C.Y., et al. International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017;152(8):1975–84.e8. DOI: 10.1053/j.gastro.2017.02.038
13. Trivedi P.J., Crothers H., Mytton J., Bosch S., Iqbal T., Ferguson J., Hirschfield G.M. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020;159(3):915–28. DOI: 10.1053/j.gastro.2020.05.049
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022
15. Al Mamari S., Djordjevic J., Halliday J.S., Chapman R.W. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34. DOI: 10.1016/j.jhep.2012.10.013
16. Lindström L., Hultcrantz R., Boberg K.M., Friis-Liby I., Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841–6. DOI: 10.1016/j.cgh.2012.12.032
17. Goode E.C., Clark A.B., Mells G.F., Srivastava B., Spiess K., Gelson W.T.H., et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology. 2019;69(5):2120–35. DOI: 10.1002/hep.30479
18. Rupp C., Bode K.A., Leopold Y., Sauer P., Gotthardt D.N. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4):1380–9. DOI: 10.1016/j.bbadis.2017.09.012
19. Jendrek S.T., Gotthardt D., Nitzsche T., Widmann L., Korf T., Michaels M.A., et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66(1):137–44. DOI: 10.1136/gutjnl-2016-311739
20. Vesterhus M., Holm A., Hov J.R., Nygard S., Schrumpf E., Melum E., et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol. 2017;66(6):1214–22. DOI: 10.1016/j.jhep.2017.01.019
21. Trivedi P.J., Tickle J., Vesterhus M.N., Eddowes P.J., Bruns T., Vainio J., et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67(6):1135–45. DOI: 10.1136/gutjnl-2016-312354
22. Ehlken H., Wroblewski R., Corpechot C., Arrive L., Lezius S., Hartl J., et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut. 2016;65(7):1230–2. DOI: 10.1136/gutjnl-2016-311452
23. Bjornsson E., Lindqvist-Ottosson J., Asztely M., Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):502–8. DOI: 10.1111/j.1572-0241.2004.04106.x
24. Petrovic B.D., Nikolaidis P., Hammond N.A., Martin J.A., Petrovic P.V., Desai P.M., Miller F.H. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci. 2007;52(12):3499–506. DOI: 10.1007/s10620-006-9720-1
25. Sheptulina A.F., Shirokova Y.N., Ivashkin V.T. Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):52–63 (In Russ.). DOI: 10.22416/1382-4376-2016-26-3-52-63
26. de Vries E.M., de Krijger M., Färkkilä M., Arola J., Schirmacher P., Gotthardt D., et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology. 2017;65(3):907–19. DOI: 10.1002/hep.28963
27. Eaton J.E., Dzyubak B., Venkatesh S.K., Smyrk T.C., Gores G.J., Ehman R.L., et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016;31(6):1184–90. DOI: 10.1111/jgh.13263
28. Schmeltzer P.A., Russo M.W. Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis. J Clin Med. 2021;28(19):4476. DOI: 10.3390/jcm10194476
29. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–94. DOI: 10.4065/75.7.688
30. Goet J.C., Floreani A., Verhelst X., Cazzagon N., Perini L., Lammers W.J., et al. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol. 2019;71(5):992–9. DOI: 10.1016/j.jhep.2019.06.012
31. Vesterhus M., Hov J.R., Holm A., Schrumpf E., Nygard S., Godang K., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015;62(1):188–97. DOI: 10.1002/hep.27825
32. Saffioti F., Roccarina D., Vesterhus M., Hov J.R., Rosenberg W., Pinzani M., et al. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. Eur J Clin Invest. 2019;49(5):e13088. DOI: 10.1111/eci.13088
33. Eaton J.E., Vesterhus M., McCauley B.M., Atkinson E.J., Schlicht E.M., Juran B.D., et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology. 2020;71:214–24. DOI: 10.1002/hep.30085
Supplementary files
Review
For citations:
Dolgushina A.I., Selyanina A.A., Dubrovina V.V., Isyangildina G.A., Olevskaya E.R. Prognostic Models of Primary Sclerosing Cholangitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(5):43-50. https://doi.org/10.22416/1382-4376-2022-32-5-43-50
Views:
1008
Email this article 
